Life Sciences

Troutman Sanders Life Sciences practice provides the technical knowledge and business know-how to help U.S. and foreign clients achieve their business objectives.

Our team represents clients from a variety of life sciences and associated technology industries, including small, mid-sized, and large pharmaceutical, medical device and biologics companies, academic and research institutions, and investment and financial services firms. We have extensive experience helping companies at all stages of growth and maturity to navigate the myriad of legal and business issues, from product conception to development, clinical testing through regulatory approval, financing, sales and marketing, compliance, and litigation. In an environment that has become increasingly challenging, we appreciate that clients’ needs are constantly changing, and we combine our legal, technical and business experience to provide efficient and innovative solutions.

Our lawyers have deep experience across a broad range of sectors:

  • Biologics
  • Biotechnology
  • Botanical Products
  • Chemicals
  • Cosmetics
  • Diagnostics
  • Dietary Supplements/Nutraceuticals
  • Drug Delivery
  • Medical Consumables
  • Medical Devices
  • Medical Research
  • Nanotechnology
  • Pharmaceuticals
  • Sequencing
  • Vaccines
  • Veterinary Medicine

Many of our lawyers, patent agents and scientific advisors have advanced degrees in relevant life sciences disciplines, as well as professional experience in technological specialties. Our team consists of:

  • 26 lawyers with undergraduate degrees in scientific or clinical fields, including chemistry, biology, microbiology, biomedical engineering, biochemistry, molecular genetics, mechanical engineering and chemical engineering
  • 19 lawyers and intellectual property professionals with Ph.D.s or master’s degrees in scientific fields

We are well-versed in cross-border and international matters and have advised both U.S. and international companies in the life sciences sector. With our extensive experience in multi-jurisdictional corporate, capital-raising and other transactions, litigation and IP-related counseling, we give our clients an edge in product development, product protection, and enforcement of intellectual property rights and risk management. The complex nature of our work is reflected in engagements that our clients entrust us to handle across many different legal disciplines including:

Representative Experience

  • Served as lead intellectual property counsel for a major pharmaceutical company in its $32 billion takeover bid of another pharmaceutical company. Work included review of more than 20 commercial and pipeline products that focus on rare disease treatments.
  • Successfully represented Indivior in ANDA litigation against Actavis and Par relating to Indivior’s blockbuster opioid dependence treatment product, Suboxone® Film. Secured a favorable trial decision from the Federal District Court in Delaware that the defendants’ respective proposed generic products would infringe one of Indivior’s Orange Book-listed patents, that the asserted claims of that patent are valid, and enjoining defendants from launching their generic products until expiration of the patent.
  • Represented Johnson & Johnson in pharmaceutical and medical device litigation, often serving as national or regional trial counsel for industry-leading products. Represented Ethicon, a subsidiary of J&J and one of four primary manufacturers of pelvic mesh products facing litigation nationwide, in its first trial in the U.S. with over 10,000 cases pending across the country.
  • Advised Cynapsus in a transaction with Sunovion Pharmaceuticals Inc., which acquired Cynapsus for about $635 million in an all-cash transaction. Acted as issuer’s counsel for Cynapsus in an initial public offering of common shares in which $72.5 million was raised.
  • Handled due diligence and transaction drafting for a major pharmaceutical company in its $6.5 billion acquisition of a biotechnology company focused on the treatment of hereditary angioedema, or HAE. Also counseled on royalty provisions, trademark coverage, ownership issues, and patent exclusivity.
  • Served as foreign counsel to Shanghai Fosun Pharmaceutical, a leading Chinese health care provider, in the acquisition of an 86% stake in the Hyderabad-based Gland Pharma, an Indian generic injectable pharmaceutical products company backed by global private equity giant KKR & Co LP for $1.26 billion. The transaction is the largest acquisition of an Indian company by a Chinese buyer and is subject to regulatory approvals in China, India and the U.S.
More + Less -
PrintPDF

Contact